Apnimed

APMDNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$1.092 B

$26.22 -9.59%

Close of 21 Sept 2026

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

4,801,823

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#147MannkindMNKD$1.13B
#148SavaraSVRA$1.12B
#149ApnimedAPMD$1.09B
#150Obsidian TherapeuticsOBX$1.07B
#151MoonLake ImmunotherapeuticsMLTX$1.07B

Insiders buying

All insider buying →

2 open-market purchases by officers and directors of Apnimed, worth $5.20M. Grants and option exercises are excluded.

Morningside Venture Investments Ltd$5.00M
312,500 shares at $16.00 on 3 Aug 2026 · filed 5 Aug 2026
Paul J. Sekhri$200.0K
12,500 shares at $16.00 on 3 Aug 2026 · filed 3 Aug 2026

What if Apnimed were worth as much as…

Open the what-if tool →

Gold $30.3T

$727,203.64

Per share 27,735× higher

Bitcoin $1.72T

$41,310.87

Per share 1,576× higher

Nvidia $5.48T

$131,629.97

Per share 5,020× higher

Or at a round number

$2.00B $5.00B $10.0B $20.0B

Where these numbers come from

Share counts and financials for Apnimed are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.